### **Overview** Syngene International Ltd., incorporated in 1993, is one of India’s first and largest **integrated Contract Research, Development, and Manufacturing Organizations (CRDMOs)**. As a **publicly listed subsidiary of Biocon Limited**, Syngene operates independently and delivers end-to-end scientific services across **drug discovery, development, and commercial manufacturing** for small and large molecules. It serves a broad spectrum of global clients in pharmaceuticals, biotechnology, animal health, consumer goods, nutrition, and specialty chemicals. The company has evolved from a contract research organization (CRO) into a **globally competitive CRDMO**, offering integrated solutions that streamline the R&D-to-manufacturing value chain for its clients, reducing time-to-market and innovation costs. --- ### **Business Model & Strategic Positioning** Syngene operates through **three core divisions**: 1. **Research Services** – Early-stage discovery through preclinical and clinical development. 2. **Large Molecule CDMO (LM CDMO)** – End-to-end biologics development and commercial manufacturing. 3. **Small Molecule CDMO (SM CDMO)** – Full lifecycle support from API development to commercial-scale GMP manufacturing. The company employs a **twin-engine strategy**: balancing **research services (CRO)** and **development & manufacturing (CDMO)** to mitigate client demand volatility and maintain revenue resilience. It further differentiates itself through **flexible collaboration models**, including: - **Dedicated R&D Centers** (ring-fenced, client-exclusive infrastructure and teams), - **Full-Time Equivalent (FTE)** models, and - **Fee-for-Service (FFS)** arrangements. --- ### **Key Developments & Strategic Milestones (2023–2025)** #### 📍 **Acquisitions & Expansion: Strengthening Global Footprint** - **Dec 2023 (Acquisition of Stelis Biopharma Unit 3):** - Acquired a **multi-modal biologics manufacturing facility in India** for ₹617 crores ($75 million), fully funded through internal accruals. - Added **20,000 liters of drug substance capacity** and, critically, **immediate commercial-scale fill-finish capabilities**, accelerating Syngene’s biologics downstream timeline by years. - Facility is located near **Biocon Park, Bengaluru**, enabling operational synergies and oversight. - **Mar 2025 (Acquisition of Emergent’s Bayview Facility, Baltimore, USA):** - Acquired a **state-of-the-art biologics manufacturing site** in Maryland, marking Syngene’s **first commercial-scale manufacturing presence in the U.S.** - Purchase price: **$36.5 million**, part of a $50 million strategic investment. - Adds **multiple monoclonal antibody (mAb) production lines**, increasing Syngene’s **global single-use bioreactor capacity to 50,000 liters**. - Enables **USDA compliance** for animal health products and supports **U.S.-domestic outsourcing requirements**, unlocking a major customer segment. #### 🌍 **Strategic Rationale** - Positioned to serve **global biopharma clients** with **geographically resilient**, dual-location supply chains (India + USA). - Addresses **“China+1”** and **“Inflation Reduction Act (IRA)”** driven supply chain diversification trends. - Enables **end-to-end biologics services** — from cell line development to commercial supply — across human and animal health. - Facility is **expected to be fully operational in H2 FY26**, supporting **anchor clients** in both human and animal health. #### ✅ **Integrated Capabilities Across Molecules & Modalities** Syngene offers **end-to-end services** for multiple therapeutic modalities: - **Small Molecules:** Discovery to commercial API manufacturing. - **Large Molecules:** Monoclonal antibodies, bispecifics, recombinant proteins, mRNA, plasmid DNA, live biotherapeutics (LBPs). - **Advanced Modalities:** Antibody-Drug Conjugates (ADCs), oligonucleotides, peptides, PROTACs, cell & gene therapies. **Proprietary Platforms & Innovations:** - **SynVent™**: Integrated drug discovery platform managing full program delivery. - **SARchitect™**: Proprietary 3D data visualization tool for SAR optimization and cross-team collaboration. - **Syn.AI™**: AI/ML platform accelerating target identification, hypothesis generation, and lead optimization. - **N-1 Perfusion Technology**: Proprietary process enhancing cell culture productivity and titer for cost-effective commercial biologics. --- ### **Operations & Infrastructure** #### 🔬 **Facilities & Geographic Presence** - **Four Global Campuses:** - **Bangalore (HQ)** – Primary hub for R&D, biologics manufacturing, clinical development, and dedicated centers. - **Mangalore** – Commercial-scale **US FDA-approved API manufacturing site** with **70,000L capacity**. - **Hyderabad** – Expanding R&D campus in "Genome Valley"; focus on Discovery Chemistry, Biology, and Oligonucleotide development. - **Baltimore, USA** – Newly acquired **cGMP biologics site**, expanding U.S. commercial footprint. - **Total Infrastructure:** Over **2.5 million sq. ft.** of specialized R&D, manufacturing, and clinical development space. - **Regulatory Approvals:** Facilities approved by **US FDA, EMA, UK VMD, Health Canada, and PMDA**; **AAALAC accredited** and **GLP-certified**. #### 👥 **Workforce & Talent** - **Total Employees:** Over **8,200**, including **5,600+ scientists** (approx. 500 PhDs). - Strategic focus on **talent development**, digitization, and leadership under programs like *‘My Future Plan’*. - Dedicated R&D centers for **Amgen, Bristol Myers Squibb (BMS), and Baxter**, hosting over **1,100 scientists**. - The BMS center, established in 2009, is **Asia’s largest dedicated R&D center**. --- ### **Service Offerings** #### 1. **Research Services** - **Discovery Chemistry & Biology:** Hit-to-lead programs across small and large molecules. - **Integrated Drug Discovery (IDD):** SynVent platform supporting end-to-end project leadership. - **Safety Assessment & DMPK:** GLP toxicology, ADME, and in vivo pharmacology. - **Translational & Clinical Research:** Central lab services, bioanalysis, and clinical data management. - **Performance & Specialty Materials:** Non-pharma innovation (e.g., ionic materials for green hydrogen). #### 2. **Dedicated R&D Centers** - Custom, long-term (5–10 years), full-service R&D facilities operating as **extensions of clients’ internal teams**. - Co-location of client teams ensures **real-time collaboration**, knowledge continuity, and intellectual property (IP) security. - Successful examples: **BMS (25-year relationship)**, **Amgen (SARC center)**, **Zoetis** (10-year biologics manufacturing deal). #### 3. **Development & Manufacturing Services** - **Small Molecule CDMO:** - End-to-end **CMC, API development, and commercial manufacturing**. - FDA-compliant API plant in **Mangaluru** with capabilities in **highly potent APIs (HPAPI)** and oligonucleotide synthesis. - “Follow-the-molecule” strategy to **retain clients across development stages**. - **Large Molecule CDMO:** - GMP-compliant development and manufacturing using **single-use bioreactors**. - Services span **mAbs, bispecifics, ADCs, mRNA, plasmid DNA, and microbial products**. - **Gene-to-GMP Drug Substance in 9–12 months**, significantly faster than industry average. --- ### **Strategic Growth Initiatives (FY25–FY26)** - **Expand Total Addressable Market (TAM):** Penetrate **small-to-mid biotech firms** for early-stage projects, while deepening **large pharma partnerships**. - **Target Emerging Modalities:** Invest in **ADCs, oligonucleotides, peptides, microbial therapeutics, and ATMPs**. - **Enhance Drug Product Capabilities:** Leverage newly acquired fill-finish capacity to offer **integrated biologics solutions**. - **Digitization & Smart Manufacturing:** - Building a **“Smart Factory” ecosystem** with IoT, MES, digital twins, and AI. - Full digital integration expected by **FY26**, enabling real-time operations. - **Sustainability & Innovation:** - Developed **functional ionic materials** (4x more stable) for **clean energy applications**. - Launched **Syne-MAP**, an e-commerce platform for DMPK services (Phase I launched Jun 2025). - Reduced manufacturing costs via **N-1 perfusion tech, AI-driven optimization, and lean/six sigma**. --- ### **Client & Market Position** - **Active Clients:** ~400 global clients, including **BMS, GSK, Zoetis, Amgen, Merck KGaA, and Baxter**. - Serves **14 of the top 20 global pharma companies**. - Secured **long-term strategic agreements**, including: - **10-year contract with Zoetis** for **Librela®** (monoclonal antibody for canine osteoarthritis). - **5–10 year R&D partnerships** with Amgen, BMS, and Deerfield Discovery and Development Corp. - Strong recovery in **biotech client demand** noted post FY24 funding slowdown, with **pilot-to-contract conversion rates improving**. --- ### **Financial & Operational Highlights** - **Infrastructure Growth:** More than **doubled qualified infrastructure** to meet international standards since FY16. - **Scientific Workforce:** Grew to **5,600+ scientists (FY16–FY24)**, enhancing capabilities across modalities. - **Audits:** Underwent **111 client and regulatory audits** in FY25, reflecting rigorous **quality and compliance standards**.